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Abstract: Gene electrotransfer is an effective approach for delivering plasmid DNA to a variety of tissues. Delivery of molecules with electric pulses requires control of the electrical parameters to achieve
effective delivery. Since discomfort or tissue damage may occur with high applied voltage, the reduction of the applied voltage while achieving the desired expression may be an important improvement.
One possible approach is to combine electrotransfer with exogenously applied heat. Previous work
performed in vitro demonstrated that increasing temperature before pulsing can enhance gene expression and made it possible to reduce electric fields while maintaining expression levels. In the study reported here, this
combination was evaluated in vivo using a novel electrode device designed with an inserted laser for application of heat.
The results obtained in this study demonstrated that increased temperature during electrotransfer increased expression or
maintained expression with a reduction in applied voltage. With further optimization this approach may provide the basis
for both a novel method and a novel instrument that may greatly enhance translation of gene electrotransfer.
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1. INTRODUCTION
A critical aspect for gene therapy is appropriate delivery.
Non-viral delivery has a favorable safety profile; however,
expression levels are typically low without the addition of
physical, chemical or viral delivery methods. Physical approaches, including ultrasound, hydrodynamic pressure, and
electrotransfer, enhance delivery to a variety of tissues and
are increasingly evaluated for therapeutic applications [1-7].
Gene electrotransfer (GET; electroporation) uses electric
pulses to transiently permeabilize cell membranes allowing
entry of extracellular nucleic acids into the cell. The current
challenge is to develop protocols that result in appropriate
transfection efficiency without adverse effects [8, 9].
Skin is an excellent target for gene therapy [10-15] due to
its easy accessibility for delivery and monitoring. GET of
skin is a simple and direct method for gene therapy and can
be accomplished in a minimally invasive way. Several approaches with potential therapeutic or prophylactic applications have been evaluated including wound healing [16-18],
ischemia [19-21], infectious disease vaccines [22-25] and
cancer vaccines and therapies [5, 8, 26]. To date, sixty-eight
clinical trials are being enrolled, are ongoing, or are completed using GET (clinicaltrials.gov “electroporation”, “electrotransfer”). Most of these trials are designed to evaluate
DNA vaccines against infectious agents or cancer or the effectiveness of cancer immunotherapy [27].
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For optimal delivery GET electrodes must be designed
based on the target tissue and/or the desired endpoint analysis, for example secreted protein, antibody production, or cell
death. Therefore, important focus areas for GET research
have been electrode development and the identification of
“ideal” pulsing parameters. A variety of electrodes for
in vivo use have been developed including needle, caliper,
plate, and non-penetrating pin electrodes [23, 28, 29]. While
each electrode type has its advantages and disadvantages, the
surface electrodes are attractive because they allow for delivery of DNA non-invasively. A surface electrode design is
well-suited for delivery to the skin. However, the skin is also
well-adapted to serving as a barrier from intrusion. Our lab
has developed two surface electrodes for gene delivery to the
skin that provide high levels of transgene expression. The
first was the 4 plate electrode (4PE) designed with 4 plates at
90° angles with a stopper to maintain a constant distance
between electrodes [28].
This electrode worked well as it provided a fixed distance
and allowed for directional control of the applied electric
field in two perpendicular directions without the need for
moving the electrodes. While an advantage of this design is
the fixed distance, the treatment of larger areas also required
an increase in the electrode gap. Since the applied voltage is
based on the distance between the electrodes, higher voltages
are required to achieve effective delivery. These voltages
potentially cause cellular damage or discomfort [28, 30]. To
minimize cellular damage or discomfort, a multi-electrode
array (MEA) was designed. This applicator consisted of 16
flat pin electrodes 2mm apart in a 4X4 array [23, 29, 31].
The electrode covered the same tissue area as the 4PE but
© 2016 Bentham Science Publishers
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smaller electrode distances and an increased number of electrodes allowed for enhanced directional control and a reduction in applied voltage.

was applied at 1, 2 or 3 amps and temperature measured in
real time.

Despite many successes of GET and the development of
an increasing number of GET-based therapies, further improvement is needed, for example by reducing the necessary
applied voltage and by increasing the ability to control expression. While GET is generally a non-thermal process, the
administration of low heat from an exogenous source could
potentially enhance delivery. Changes in both skin and core
body temperature have been demonstrated to affect vasodilation and constriction. Additionally, local warming of tissue
increases vasodilation, reaching a maximum blood flow in
the skin at 42°C. This effect is maintained for up to one hour
after heating [32-34]. The use of heat to enhance delivery is
based on the hypothesis that permeability of cell membranes
can be affected by temperature [35]. For example, hyperthermia has been used to enhance delivery of chemotherapeutics [36-39]. Increased temperature can influence the efficiency of electrotransfer while decreasing the temperature
to 4oC reduces delivery [35].

2.4. Electrode Design

The goal of the current study was to determine if thermal
assisted gene electrotransfer (TAGET) could enhance transgene expression and/or allow for a reduction of applied voltages in vivo. We hypothesized that moderate heating prior to
GET in vivo would allow the use of lower applied voltages
while maintaining gene expression without adverse effects
on the tissue.
2. MATERIALS AND METHODS
2.1. Animals
Animals used for this study were 6-8 weeks old Female
Hartley guinea pigs weighing approximately 200-250g. The
animals were housed at the Old Dominion University animal
facility and procedures approved by the Old Dominion Institutional Animal Care and Use Committee.
2.2. Plasmids
Endotoxin free preparations at 2mg/ml in physiological
saline of gWizLuc,encoding firefly luciferase and gWizGFP
green fluorescence protein (GFP) were purchased (Aldevron,
Fargo, ND) in this study. Plasmids were prepared endotoxin
free by Aldevron (proprietary fermentation technology and
DNA purification) and suspended at 2mg/ml in physiological
saline.
2.3. Heat Application
Animals were anesthetized with O2 containing 2.5-3.0%
isoflurane. Both left and right flanks were shaved using
Wahl Shears and extraneous hair removed by cleansing with
water. To determine the intradermal skin temperature from
exogenous heating, an 18G needle was inserted intradermally into the left or right flank then replaced with a thermocouple temperature probe (Omega, Stamford, CT, USA).
Baseline tissue temperature readings were recorded. Temperature measurements during heat application and GET
were collected by positioning the electrode array on the
skin above the temperature probe. Exogenous laser heat

Electric pulses were administered utilizing a specially
constructed applicator. The electric pulse delivery system
had an integrated infrared radiation emitter Fig. (1) to heat
the tissue radiatively. The emitter consisted of an optical
fiber centered between 4 pins with rounded ends spaced 5
mm apart that acted as electrodes. The optical fiber has advantages over other nonionizing radiation emitters: its small
diameter (< 1 mm) and dielectric material can be easily integrated into an existing electrical pulse delivery system. The
fiber was connected to an infrared semiconductor laser
which provided up to 8W of radiative power at a wavelength
of approximately 1m. Adjusting the distance of the fiber to
the tissue irradiated a well-defined circular area of the tissue.
2.5. Gene Delivery
Injection sites were marked to ensure accuracy of data
collection. Gene delivery and TAGET were assessed after
intradermal injections of 50 l of plasmid to multiple sites on
both left and right flanks. The electrode array was positioned
over the injection area with or without exogenous heating.
The heat was applied as determined in the first round of experiments at 1 amp for 30 seconds. The tissue remained at
43°C for approximately 10 seconds, allowing adequate time
for pulsing at a range of voltages from 50-125V for luciferase experiments and 50-100V for GFP experiments.
Based on our previously published results with a similar
electrode, pulse number, time between pulses and pulse
length were maintained at 8 pulses, 150ms, and 150ms, respectively [23, 29, 31].
During the course of these experiments we evaluated
laser amperage, duration of thermal assistance and applied
voltage. Gene expression levels were measured for all conditions by in vivo bioluminescent imaging or fluorescent imaging. Visual assessment of the skin was used to determine the
extent of external tissue damage from the addition of moderate heat.
2.6. In Vivo Bioluminescent Imaging
On days 1, 2, 5, 7, 10, and 14, animals were anesthetized
with O2 containing 2.5-3.0% isoflurane followed by injections of 50 l of 15 mg/ml D-luciferin (Gold Biotechnology,
St. Louis, MO) at the plasmid injection sites. The animals
were confined in an anesthesia chamber for two minutes then
transferred to the IVIS® Spectrum (Perkin Elmer, Akron,
OH), imaging chamber under constant anesthesia (O2 containing 2.5% isoflurane). Regions of interest (ROI) were
selected on the image to encompass the entirety of each injection site independently and compared to untreated control
ROIs. After background correction bioluminescence results
were represented as average total flux, photons/sec (p/s).
2.7. GFP Expression and Analysis
Forty-eight hours after plasmid delivery, the animals
were euthanized and the treated areas were excised, fixed in
4% paraformaldehyde for 1-2 hours, equilibrated in optimum
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Fig. (1). TAGET Device. Schematic of an optical fiber that was connected to an infrared laser and inserted into the device. The fiber is situated centrally between 4 electrodes. The fiber is also placed 1 cm above a 3 mm opening. This gap and opening allows for an increased spot
size of the light as it exits into the space between the opening and the tissue which is set at 5 mm.

cutting temperature (OCT) compound, snap frozen using dry
ice and stored at -80°C. Samples were sectioned on a cryostat and mounted in Vectashield® mounting media with 4',
6-diamidino-2-phenylindole (DAPI; Vector Labs, Burlingame,
CA) was used for nuclear staining. Slides were imaged on an
Olympus BX51 fluorescence microscope. The analysis of the
tissues was performed in a blinded fashion. Two members of
the research team performed the evaluation independently
without knowledge of the specific treatment protocol for the
sample being evaluated.
2.8. Statistical Analysis
Temperature and luciferase measurements are represented as the mean ± SD. Comparisons between specific
voltage with or without the addition of thermal component
were performed by Student T-Test. Significance was assumed at p<0.05.
3. RESULTS AND DISCUSSION
3.1. Electrode Design, Development and Temperature
Determination
An in vivo surface array was designed that incorporated
features from both the 4PE and MEA [23, 28-31]. This new
array consisted of four electrodes with 5mm length and 5mm
gap. Centered within the array was an infrared laser which
sat flush to the electrode handle and applied a focused beam
of light to the skin (Fig. 1). The electric pulses were administered in 2 sets of four pulses orthogonally. As shown in the
schematic (Fig. 2), the pulses were administered simultaneously from the electrodes for four pulses (i.e., from 1 and 4
to 2 and 3) then using a manual switch the direction was rotated 90° and pulses administered for four additional pulses
(1 and 2 to 4 and 3). Fig. (2) provides the full final protocol
for administration of TAGET (not to scale). The total time
required for 1 treatment was approximately 45 seconds.
In a previous in vitro study we evaluated the use of low
and moderate heat conditions prior to application of GET to
increase gene expression and determine if reduction in absolute voltage could achieve a reduction in cell mortality [40].

This study demonstrated that the application of moderate
levels of heat could achieve increased gene expression, although utilizing maximal electric fields came at the expense
of cell viability. Interestingly, we found that when moderate
exogenous heat was applied prior to pulsing, similar gene
expression levels could be achieved using about 30% lower
electric fields. These increased gene expression levels were
obtained with a significantly higher level of cell viability. An
important observation from this work was that temperatures
higher than 43°C resulted in increased cell death [40] while
lower temperatures did not produce consistently higher gene
expression. Therefore, 43°C was used for all in vivo experiments.
The first set of experiments was designed to determine
the time it took to heat the tissue to 43oC. Using a temperature probe inserted laterally into the dermis of the guinea pig,
the time to reach 43°C was measured from application of
direct currents between 1 and 3 amps. Averages of 29 (+/-4),
23 (+/-7), and 17 (+/-2) seconds were measured for 1, 2, and
3 amps respectively (Fig. 3A). However, at both 2 and 3
amps the temperatures continued to rise quickly beyond
43°C. A consistent rise in heating was obtained by using 1
amp for 30 seconds. In addition, the temperature probe was
left inserted in the skin after heating and application of
TAGET to determine the increase in temperature at the end
of delivery. Consistent with the previously published in vitro
results and reports on the lack of heat generation from reversible electroporation, changes in temperature were less
than 1°C. However, minimal visual damage that typically
healed within 2-4 days was noted at the location of electrode
contact (Fig. 3B, C).
3.2. Evaluation of In Vivo Luciferase Gene Expression
After TAGET
Luciferase expression was measured to determine
whether the addition of heat prior to GET would enhance
expression in vivo over time. Injection of DNA only, thermally assisted injection of DNA, and GET were included as
controls in these experiments. Guinea pigs received an intradermal injection of 50 l gWizLuc on Day 0 immediately
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Fig. (2). Experimental Setup and Delivery Protocol. Upper panel: The pulse sequence is outlined. All 4 electrodes are active for each pulse,
but are applied in two perpendicular directions in sequence. Four pulses in one direction followed by four in a perpendicular direction. Lower
panel: schematic of the delivery protocol to the skin.

followed by TAGET consisting of 30 seconds of heating at 1
amp at an applied voltage of 125V, 8 pulses for 150ms.
Luciferin was injected into the same location as treatment on
Days 1, 2, 7, and 14 and photon emissions measured on the
IVIS Spectrum. No differences between the application of
DNA + heat as compared to DNA alone were observed and
as expected both had lower expression than DNA + GET
(Fig. 4). Interestingly the greatest differences between
TAGET and GET were noted at Day 2 (a 12 fold increase).
On Day 7, the greatest difference (6-8000 fold) observed was
between TAGET and DNA injection. At Day 14 TAGET
groups decreased below the levels of GET.

was injected and the site treated with and without heat and
with and without GET at 50 and 100V. After 48 hours, increased GFP protein expression was observed in TAGET
groups (Fig. 6); however, deeper penetration into the dermis
was not observed. As with GET, the use of TAGET appears
to localize expression within the epidermis.
Time(s) to increase Dermal temperature to 43C
35
30

3.3. Location of Gene Expression by TAGET
A disadvantage of surface electrodes is their inability to
penetrate deep into the tissue without using high potentially
damaging electric fields. The addition of heat prior to GET
might facilitate delivery and might produce gene expression
deeper within the tissue. To analyze this, gWizGFP plasmid

Time (seconds)

25

While the addition of heat alone did not result in
enhanced gene expression as compared to injection of DNA
alone, the combination of heat pretreatment and GET did
result in higher gene expression at specific time points.
Therefore, we sought to determine the most appropriate GET
voltage condition for enhancing gene expression with
thermal assistance. The previous heating conditions were
maintained, but the applied voltage varied from 50 to 125V
(Fig. 5A). The highest gene expression was achieved at an
applied voltage of 100V with or without the addition of heat.
However, the addition of heat at 50V resulted in significantly
(p<0.05) increased gene expression as compared to GET
alone at Days 6 and 7 (Fig. 5B). Significant (p<0.05) gene
expression increases were also noted at the same time points
for 100V. TAGET at lower voltages resulted in similar gene
expression levels as higher voltage GET conditions. For
example expression levels achieved with TAGET at 50V
were similar to levels following 100V GET (Fig. 5B).

20
15
10
5

A

B

0
1 Amp
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C

Fig. (3). Thermal Application Timing and Effect on Skin. (A)
Comparison of various laser amperages and the time necessary to
increase intradermal skin temperature to 43°C. Error is represented
as standard deviation (SD). (B) Evaluation of tissue damage by
visual analysis after application of heat and prior to pulsing. (C)
Evaluation of tissue damage by visual analysis after application of
heat and after pulsing.
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applied voltage, targeted application of heat could aid in localization of plasmid expression. Future studies will evaluate
alternate electrode designs, heat application and electrical
parameters with the goal of optimizing the applications of
in vivo TAGET.
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Fig. (4). Gene Expression Resulting from TAGET. Luciferase gene
expression was evaluated during a 2 week time course following
delivery with or without heat pretreatment and GET. 8 pulses of
150ms were administered with an applied voltage of 125 with heat
(HE) or without heat (ET). This was compared to injection of plasmid DNA with heat (IO + H) or without heat (IO). Error is represented as SD.
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CONCLUSION

We did not demonstrate an increased depth of penetration
for gene delivery. However, there were several parameters
which were not evaluated. Throughout the current experimental design the heat level and duration at 43oC and pulse
number, length, and interval were maintained. In the future,
these parameters could be adjusted to assess the effect of
their changes. GET parameters can be designed to increase
penetration by changing electrode distance or electric field
[28, 29]. The current electrode design could be adjusted to
evaluate the combination of these factors by reducing the
electrode distance or increasing the field.
While this method still requires optimization, the initial
results suggest that TAGET could prove to be a valuable tool
for obtaining better control over delivery and subsequent
protein expression. In addition, to the overall reduction of

1E+010

Total Flux (photons/sec)

In this study, we demonstrated a novel method of in vivo
GET employing exogenous heat. The intradermal skin temperature was increased to 43°C using an infrared laser and
electrical fields applied via electrodes. We previously demonstrated that the addition of exogenous heat to GET in vitro
resulted in maximal gene expression with a reduction of applied voltage by 30% and an increase in cell viability [40].
This current study demonstrated that in vivo TAGET maintained gene expression levels while utilizing 50% lower applied voltage with only short-term adverse effects to the tissue. In addition to gene expression, our current study also
demonstrated that TAGET did not result in temperature increases above those induced by the exogenous heating
source.
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(B)
Fig. (5). Comparison of Various Applied Voltages with or without
Heat Pretreatment. Luciferase gene expression was evaluated with
GET administered at various applied voltages. Baseline values of
IO and HIO were also determined. (A) Applied voltages were administered from 50-125 with (HE) or without (ET) heat pretreatment. (B) Enlarged graph highlighting differences at 50 and 100
volts with and without heat pretreatment. All errors are represented
as SD.
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Fig. (6). Evaluation of Distribution Following TAGET Delivery of gWizGFP. Plasmid encoding GFP was delivered by GET with or without
heat pretreatment at applied voltage of 50 or 100. Tissue was harvested at 48 hours, sectioned, counter stained with Dapi, and fluorescent
image analyzed.
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